Identifying bona fide hits efficiently and effectively is a challenge in any small molecule drug discovery program. Using the appropriate assays for screening and hit-to-lead is an important determinant of success, but choosing from among the myriad types of assays can be a daunting process. ADP detection simplifies discovery, providing a universal approach to targeting kinases. The Transcreener ADP2 Kinase Assay is the only method available with direct detection of ADP. Alternative ADP detection assays use complex enzymatic coupling mechanisms making them prone to assay interference and generating false positives that require time-consuming counter-screens to triage. Transcreener’s sensitivity reduces the quantity of enzyme and substrate required saving you valuable resources during your screen. And while the assay’s flexibility and simplicity make it an excellent fit for HTS, there are also distinct advantages in SAR and MOA studies.
In this webinar we will discuss:
- Sensitive detection of kinase initial velocity over a broad range of ATP concentrations, critical for screening such a diverse class of targets
- Compound interference comparisons between Transcreener and other HTS assays
- Compatibility with 1536 well-miniaturized formats along with overnight and reagent signal stability that provide flexibility in liquid handling
- Using kinase assays for kinetic studies such as residence time determination
- Measuring accurate IC50 values, even for potent kinase inhibitors due to robust assay signal at low enzyme concentration